Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity
about
Subcellular localization of dihydropyrimidine dehydrogenaseIdentification of genes conferring resistance to 5-fluorouracilCrystal structure of the productive ternary complex of dihydropyrimidine dehydrogenase with NADPH and 5-iodouracil. Implications for mechanism of inhibition and electron transferProlonged severe 5-fluorouracil-associated neurotoxicity in a patient with dihydropyrimidine dehydrogenase deficiencyHigh-dose 5-fluorouracil infusional therapy is associated with hyperammonaemia, lactic acidosis and encephalopathyPharmacogenetic aspects in treatment of colorectal cancer--an update.Fluorouracil and the new oral fluorinated pyrimidines.Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency.Therapeutic drug monitoring of antimetabolic cytotoxic drugs.5-fluorouracil pharmacokinetics: causes for variability and strategies for modulation in cancer chemotherapy.Screening and diagnosis of beta-ureidopropionase deficiency by gas chromatographic/mass spectrometric analysis of urine.Impact of 5-fluorouracil metabolizing enzymes on chemotherapy in patients with resectable colorectal cancer.Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosingSelection of extreme phenotypes: the role of clinical observation in translational research.Pharmacogenetics of cancer therapy: getting personalCandidate gene approach for pharmacogenetic studies.The effect of dihydropyrimidine dehydrogenase deficiency on outcomes with fluorouracil.Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics.The impact of pharmacogenomics on gastrointestinal cancer therapy.Pharmacogenetics and pharmacogenomics of anticancer agents.Pharmacogenomics: marshalling the human genome to individualise drug therapyPhase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study.Recent developments in the clinical pharmacology of classical cytotoxic chemotherapy.Ancestry and pharmacogenetics of antileukemic drug toxicityPyrimidine degradation defects and severe 5-fluorouracil toxicity.Tailored chemotherapy for colorectal cancer: a new approach to therapy.Genetic factors influencing pyrimidine-antagonist chemotherapy.Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer.Advances and challenges in fluoropyrimidine pharmacogenomics and pharmacogenetics.Predicting 5-fluorouracil toxicity in colorectal cancer patients from peripheral blood cell telomere length: a multivariate analysis.Side effects during chemotherapy predict tumour response in advanced colorectal cancerPhase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study GroupReduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene.Analysis of the time course and prognostic factors determining toxicity due to infused fluorouracil.5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil.Insights into the role of heritable genetic variation in the pharmacokinetics and pharmacodynamics of anticancer drugs.Evaluation of clinical value of single nucleotide polymorphisms of dihydropyrimidine dehydrogenase gene to predict 5-fluorouracil toxicity in 60 colorectal cancer patients in ChinaDihydro pyrimidine dehydrogenase deficiency in patients treated with capecitabine based regimens: a tertiary care centre experience.A DPYD variant (Y186C) in individuals of african ancestry is associated with reduced DPD enzyme activityClinically available pharmacogenomics tests
P2860
Q24322064-ABFC865D-552A-4400-AD86-1E553EEC265FQ24655818-24FEF75B-695C-42D2-90E8-9349A461A5EFQ27637379-20132787-BDC2-4A22-BD9A-A37136937FE4Q28372607-2547B385-F78D-4886-A177-BFDFA70EDA0EQ28379450-FAF6C11D-088C-452E-819D-79D65DEBA21BQ30336665-CEF1AF94-2C14-45AD-B426-AB966A6B5E00Q32052960-95E02D56-503B-47B7-9A36-D44E9409D4ECQ33432892-A1D896BE-909D-457A-A87D-716304D5615EQ33586713-758FDDD3-7FE9-41B3-9F74-36EDD32115CDQ33750445-922BD130-53CC-453F-92AB-36E7B324DEB2Q33961562-48053CB2-02E3-4AC1-A87D-C77BCD0F13E6Q34000605-411BE3A7-AD7C-4234-AC17-EE1A953BE9C6Q34367423-7361AD62-0511-4FA3-A9D1-7E304C484872Q34384968-67438568-1D6B-45B4-A205-FCB0E41D3EF5Q34386321-340F4212-1E87-4CDA-AFB1-1191E0999D61Q34609133-05D33307-1C82-4313-A0CD-AE1AFB42153DQ34761260-BC062C62-91C7-4AE9-B225-7203BA9023D7Q34775315-6917FDED-419F-4411-92D2-85E7A610674FQ34837030-A8CD46F5-095A-4DDF-A8BC-AE6978CD313CQ35030489-1B690E81-DC1D-4127-A5E1-CEE293941A59Q35090217-FB818C32-1F20-4990-BA3B-99C9897F8AA3Q35765841-1D6DA309-185A-4260-8417-54EE98F18870Q35827602-1E2BDEC5-BE19-4963-9662-7B5E984C1537Q35828717-08D8467B-1CBC-4B5E-99CC-D5E98EF0A896Q35967209-71407B25-47EA-49A4-B619-9C8550F6587FQ35973877-55F3A42D-0FC6-4A7D-8B28-06F543E6A7EBQ36205831-3FD76A0B-76B2-4140-95AB-F25D839A641CQ36295110-172BC0B5-B00F-4BDF-BEED-DFA5BB927642Q36317002-A7CE2705-E83F-4C59-B152-9DA112F0D9DAQ36385305-7399BC4C-CE55-4CF4-9DDA-7602C7C35A76Q36615421-541751FB-1BC9-47DA-A64B-718813524D03Q36621749-B6F1099F-70D4-4F70-9C54-A96B03A4F475Q36623852-631DD77B-225C-451A-B801-589388790E4DQ36648876-9FB393A0-5BF7-442C-8ABA-CC777A0A4E5FQ36688040-B022D33B-9780-46EC-BD25-21AB4ACC3DAFQ36847276-C7CE606A-DDCA-4038-BC18-23F9CCB750A2Q36909839-230A3803-CD22-4E6B-945B-079A8C717517Q36936972-8B5A4CC1-D139-4BB5-895D-9D01E071FCFFQ37290672-F7006EEB-E9AA-4C74-B7A1-8BF3405EA653Q37314487-FB1BBD97-F86B-44C1-87AE-08A078335B88
P2860
Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity
description
1988 nî lūn-bûn
@nan
1988 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1988 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
name
Familial deficiency of dihydro ...... -fluorouracil-induced toxicity
@ast
Familial deficiency of dihydro ...... -fluorouracil-induced toxicity
@en
Familial deficiency of dihydro ...... -fluorouracil-induced toxicity
@nl
type
label
Familial deficiency of dihydro ...... -fluorouracil-induced toxicity
@ast
Familial deficiency of dihydro ...... -fluorouracil-induced toxicity
@en
Familial deficiency of dihydro ...... -fluorouracil-induced toxicity
@nl
prefLabel
Familial deficiency of dihydro ...... -fluorouracil-induced toxicity
@ast
Familial deficiency of dihydro ...... -fluorouracil-induced toxicity
@en
Familial deficiency of dihydro ...... -fluorouracil-induced toxicity
@nl
P2093
P2860
P356
P1476
Familial deficiency of dihydro ...... -fluorouracil-induced toxicity
@en
P2093
J T Carpenter
R B Diasio
T L Beavers
P2860
P356
10.1172/JCI113308
P407
P577
1988-01-01T00:00:00Z